Resolve Biosciences, a Monheim am Rhein, Germany-based molecular cartography technology company, raised $71m in Series B funding.
The round was led by Patient Square Capital with participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK.
The company, which has now raised more than $100m, intends to use the funds to scale operations and accelerate product development to meet demand worldwide.
Led by CEO Jason T. Gammack, Resolve Biosciences is applying Molecular Cartography™ to enable scientists to gain insights based on the resolution view of spatial biology. The proprietary, highly multiplexed, single-molecule fluorescence in situhybridization technology offers three-dimensional spatial context at subcellular resolution in a fully automated process. The platform provides the required sensitivity, specificity, and workflow convenience to illuminate critical mechanisms, map interactions, and elucidate the cell’s complex transcriptional landscape without destroying the tissue section or cell culture sample. The technology is modular and flexible, and is expected to incorporate the interrogation of DNA, protein, and metabolomic data layers in the future. The technology offers sensitivity and specificity to help scientists detect individual transcripts and rare signals to interpret fundamental biology and advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, infectious disease, and agriculture.
Resolve Biosciences has a North American facility and laboratory in San Jose, Calif.
FinSMEs
25/10/2022